| Bioactivity | Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis[1]. | ||||||||||||
| Invitro | Bioymifi (3-10 µM) induces caspase-8-dependent apoptosis. At a 10-μM concentration, Bioymifi induces processing of caspase-3 into smaller fragments[1].Bioymifi induces apoptosis via death receptor DR5. Bioymifi promotes DR5 aggregation and activation. Bioymifi shares the same DR5-dependent extrinsic apoptotic pathway with TRAIL. Binding of bioymifi to DR5 recruits FADD, which in turn engages with the apical caspase-8 to form death-inducing signaling complex (DISC) Bioymifi (3-10 µM) induces caspase-8-dependent apoptosis. At a 10-μM concentration, Bioymifi induces processing of caspase-3 into smaller fragments[1]. | ||||||||||||
| Name | Bioymifi | ||||||||||||
| CAS | 1420071-30-2 | ||||||||||||
| Formula | C22H12BrN3O4S | ||||||||||||
| Molar Mass | 494.32 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Bioymifi
CAS: 1420071-30-2 F: C22H12BrN3O4S W: 494.32
Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a K
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.